1887

Journal of General Virology header logo

Volume 92, Issue 5

IL-28B predicts response to chronic hepatitis C therapy – fine-mapping and replication study in Asian populations Free

Abstract

Type I interferon (IFN) is used for the treatment of chronic hepatitis C virus (HCV) infection. Despite advances in antiviral therapy, a large proportion of patients remain infected following current therapies. Through a genome-wide scan, we found two variants (rs8099917 and rs12979860) in the IL-28B locus that affect the outcome of PEG-IFN and ribavirin combination therapy, consistent with recent studies ( = 6.52×10; odds ratio 2.46 and  = 8.63×10, odds ratio 2.40, respectively). Significant associations were also observed in the case of IFN monotherapy for HCV genotypes 1b and 2a. With rs8099917, HCV genotype 1b patients had a significantly lower frequency of the favourable genotype (86.6 %) compared with healthy controls (91.7 %), and HCV genotype 2a patients had an intermediate frequency (89.9 %). Similar results were found for rs12979860. Fine-mapping analysis revealed that rs8099917 had the strongest association with treatment outcome and 14 others, including four novel single nucleotide polymorphisms, had comparable associations. Haplotype analysis revealed that none of the haplotypes showed stronger association than any single marker. Early non-responders who could not achieve 2 log viral decline during the first 12 weeks of treatment had higher odds ratios for these two variants. The favourable allele of rs8099917 is also associated with initial viral decline at 2 and 4 weeks following the start of therapy. Multivariate analysis of PEG-IFN and ribavirin-treated patients showed that rs8099917 genotype, viral load, fibrosis and age were significant predictors of response to therapy. Common variation at the IL-28B locus is predictive of various IFN-based therapies for HCV independent of regimen or HCV genotype.

  • Received:
  • Accepted:
  • Published Online:
© 2011 SGM
Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.029124-0
2011-05-01
2024-04-18
Loading full text...

Full text loading...

/deliver/fulltext/jgv/92/5/1071.html?itemId=/content/journal/jgv/10.1099/vir.0.029124-0&mimeType=html&fmt=ahah

References

  1. Akuta N., Suzuki F., Kawamura Y., Yatsuji H., Sezaki H., Suzuki Y., Hosaka T., Kobayashi M., Kobayashi M. et al. 2007; Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol levels. J Hepatol 46:403–410 [View Article][PubMed]
     [Google Scholar]
  2. Barrera J. M., Bruguera M., Ercilla M. G., Gil C., Celis R., Gil M. P., del Valle Onorato M., Rodés J., Ordinas A. 1995; Persistent hepatitis C viremia after acute self-limiting posttransfusion hepatitis C. Hepatology 21:639–644 [View Article][PubMed]
     [Google Scholar]
  3. Bressler B. L., Guindi M., Tomlinson G., Heathcote J. 2003; High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. Hepatology 38:639–644 [View Article][PubMed]
     [Google Scholar]
  4. Casiraghi M. A., De Paschale M., Romanò L., Biffi R., Assi A., Binelli G., Zanetti A. R. 2004; Long-term outcome (35 years) of hepatitis C after acquisition of infection through mini transfusions of blood given at birth. Hepatology 39:90–96 [View Article][PubMed]
     [Google Scholar]
  5. Charlton M. R., Thompson A., Veldt B. J., Watt K., Tillmann H., Poterucha J. J., Heimbach J. K., Goldstein D., McHutchison J. 2011; Interleukin-28B polymorphisms are associated with histological recurrence and treatment response following liver transplantation in patients with hepatitis C virus infection. Hepatology 53:317–324[PubMed] [CrossRef]
     [Google Scholar]
  6. Chen L., Borozan I., Feld J., Sun J., Tannis L. L., Coltescu C., Heathcote J., Edwards A. M., McGilvray I. D. 2005; Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection. Gastroenterology 128:1437–1444 [View Article][PubMed]
     [Google Scholar]
  7. Conjeevaram H. S., Fried M. W., Jeffers L. J., Terrault N. A., Wiley-Lucas T. E., Afdhal N., Brown R. S., Belle S. H., Hoofnagle J. H. et al. 2006; Peginterferon and ribavirin treatment in African American and caucasian American patients with hepatitis C genotype 1. Gastroenterology 131:470–477 [View Article][PubMed]
     [Google Scholar]
  8. Desmet V. J., Gerber M., Hoofnagle J. H., Manns M., Scheuer P. J. 1994; Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 19:1513–1520 [View Article][PubMed]
     [Google Scholar]
  9. Enomoto N., Sakuma I., Asahina Y., Kurosaki M., Murakami T., Yamamoto C., Ogura Y., Izumi N., Marumo F., Sato C. 1996; Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med 334:77–82 [View Article][PubMed]
     [Google Scholar]
  10. Feld J. J., Nanda S., Huang Y., Chen W., Cam M., Pusek S. N., Schweigler L. M., Theodore D., Zacks S. L. et al. 2007; Hepatic gene expression during treatment with peginterferon and ribavirin: identifying molecular pathways for treatment response. Hepatology 46:1548–1563 [View Article][PubMed]
     [Google Scholar]
  11. Fukuhara T., Taketomi A., Motomura T., Okano S., Ninomiya A., Abe T., Uchiyama H., Soejima Y., Shirabe K. et al. 2010; Variants in IL28B in liver recipients and donors correlate with response to peg-interferon and ribavirin therapy for recurrent hepatitis C. Gastroenterology 139:1577–1585, 1585, e1–e3 [View Article][PubMed]
     [Google Scholar]
  12. Gabriel S. B., Schaffner S. F., Nguyen H., Moore J. M., Roy J., Blumenstiel B., Higgins J., DeFelice M., Lochner A. et al. 2002; The structure of haplotype blocks in the human genome. Science 296:2225–2229 [View Article][PubMed]
     [Google Scholar]
  13. Ge D., Fellay J., Thompson A. J., Simon J. S., Shianna K. V., Urban T. J., Heinzen E. L., Qiu P., Bertelsen A. H. et al. 2009; Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461:399–401 [View Article][PubMed]
     [Google Scholar]
  14. Hadziyannis S. J., Sette H. Jr, Morgan T. R., Balan V., Diago M., Marcellin P., Ramadori G., Bodenheimer H. Jr, Bernstein D. et al. 2004; Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 140:346–355[PubMed] [CrossRef]
     [Google Scholar]
  15. Hijikata M., Ohta Y., Mishiro S. 2000; Identification of a single nucleotide polymorphism in the MxA gene promoter (G/T at nt -88) correlated with the response of hepatitis C patients to interferon. Intervirology 43:124–127 [View Article][PubMed]
     [Google Scholar]
  16. Honda M., Sakai A., Yamashita T., Nakamoto Y., Mizukoshi E., Sakai Y., Yamashita T., Nakamura M., Shirasaki T. et al. 2010; Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C. Gastroenterology 139:499–509 [View Article][PubMed]
     [Google Scholar]
  17. Kenny-Walsh E. Irish Hepatology Research Group 1999; Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. N Engl J Med 340:1228–1233 [View Article][PubMed]
     [Google Scholar]
  18. Knapp S., Yee L. J., Frodsham A. J., Hennig B. J., Hellier S., Zhang L., Wright M., Chiaramonte M., Graves M. et al. 2003; Polymorphisms in interferon-induced genes and the outcome of hepatitis C virus infection: roles of MxA, OAS-1 and PKR. Genes Immun 4:411–419 [View Article][PubMed]
     [Google Scholar]
  19. Kotenko S. V., Gallagher G., Baurin V. V., Lewis-Antes A., Shen M., Shah N. K., Langer J. A., Sheikh F., Dickensheets H., Donnelly R. P. 2003; IFN-λs mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol 4:69–77 [View Article][PubMed]
     [Google Scholar]
  20. Maher S. G., Sheikh F., Scarzello A. J., Romero-Weaver A. L., Baker D. P., Donnelly R. P., Gamero A. M. 2008; IFNα and IFNλ differ in their antiproliferative effects and duration of JAK/STAT signaling activity. Cancer Biol Ther 7:1109–1115 [View Article][PubMed]
     [Google Scholar]
  21. Manns M. P., McHutchison J. G., Gordon S. C., Rustgi V. K., Shiffman M., Reindollar R., Goodman Z. D., Koury K., Ling M., Albrecht J. K. 2001; Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358:958–965 [View Article][PubMed]
     [Google Scholar]
  22. Marcello T., Grakoui A., Barba-Spaeth G., Machlin E. S., Kotenko S. V., MacDonald M. R., Rice C. M. 2006; Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology 131:1887–1898 [View Article][PubMed]
     [Google Scholar]
  23. Matsuyama N., Mishiro S., Sugimoto M., Furuichi Y., Hashimoto M., Hijikata M., Ohta Y. 2003; The dinucleotide microsatellite polymorphism of the IFNAR1 gene promoter correlates with responsiveness of hepatitis C patients to interferon. Hepatol Res 25:221–225 [View Article][PubMed]
     [Google Scholar]
  24. Naito M., Matsui A., Inao M., Nagoshi S., Nagano M., Ito N., Egashira T., Hashimoto M., Mishiro S. et al. 2005; SNPs in the promoter region of the osteopontin gene as a marker predicting the efficacy of interferon-based therapies in patients with chronic hepatitis C. J Gastroenterol 40:381–388 [View Article][PubMed]
     [Google Scholar]
  25. Ohnishi Y., Tanaka T., Ozaki K., Yamada R., Suzuki H., Nakamura Y. 2001; A high-throughput SNP typing system for genome-wide association studies. J Hum Genet 46:471–477 [View Article][PubMed]
     [Google Scholar]
  26. Pagliaccetti N. E., Eduardo R., Kleinstein S. H., Mu X. J., Bandi P., Robek M. D. 2008; Interleukin-29 functions cooperatively with interferon to induce antiviral gene expression and inhibit hepatitis C virus replication. J Biol Chem 283:30079–30089 [View Article][PubMed]
     [Google Scholar]
  27. Robek M. D., Boyd B. S., Chisari F. V. 2005; Lambda interferon inhibits hepatitis B and C virus replication. J Virol 79:3851–3854 [View Article][PubMed]
     [Google Scholar]
  28. Romero-Gómez M., Del Mar Viloria M., Andrade R. J., Salmerón J., Diago M., Fernández-Rodríguez C. M., Corpas R., Cruz M., Grande L. et al. 2005; Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 128:636–641 [View Article][PubMed]
     [Google Scholar]
  29. Sarasin-Filipowicz M., Oakeley E. J., Duong F. H., Christen V., Terracciano L., Filipowicz W., Heim M. H. 2008; Interferon signaling and treatment outcome in chronic hepatitis C. Proc Natl Acad Sci U S A 105:7034–7039 [View Article][PubMed]
     [Google Scholar]
  30. Sarrazin C., Susser S., Doehring A., Lange C. M., Müller T., Schlecker C., Herrmann E., Lötsch J., Berg T. 2010; Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients. J Hepatol [View Article][PubMed]
     [Google Scholar]
  31. Sheppard P., Kindsvogel W., Xu W., Henderson K., Schlutsmeyer S., Whitmore T. E., Kuestner R., Garrigues U., Birks C. et al. 2003; IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol 4:63–68 [View Article][PubMed]
     [Google Scholar]
  32. Suppiah V., Moldovan M., Ahlenstiel G., Berg T., Weltman M., Abate M. L., Bassendine M., Spengler U., Dore G. J. et al. 2009; IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy. Nat Genet 41:1100–1104 [View Article][PubMed]
     [Google Scholar]
  33. Suzuki A., Yamada R., Chang X., Tokuhiro S., Sawada T., Suzuki M., Nagasaki M., Nakayama-Hamada M., Kawaida R. et al. 2003; Functional haplotypes of PADI4, encoding citrullinating enzyme peptidylarginine deiminase 4, are associated with rheumatoid arthritis. Nat Genet 34:395–402 [View Article][PubMed]
     [Google Scholar]
  34. Tanaka Y., Nishida N., Sugiyama M., Kurosaki M., Matsuura K., Sakamoto N., Nakagawa M., Korenaga M., Hino K. et al. 2009; Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 41:1105–1109 [View Article][PubMed]
     [Google Scholar]
  35. Thomas D. L., Thio C. L., Martin M. P., Qi Y., Ge D., O’Huigin C., Kidd J., Kidd K., Khakoo S. I. et al. 2009; Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 461:798–801 [View Article][PubMed]
     [Google Scholar]
  36. Tsubota A., Chayama K., Ikeda K., Yasuji A., Koida I., Saitoh S., Hashimoto M., Iwasaki S., Kobayashi M., Hiromitsu K. 1994; Factors predictive of response to interferon-α therapy in hepatitis C virus infection. Hepatology 19:1088–1094 [View Article][PubMed]
     [Google Scholar]
  37. Tsukada H., Ochi H., Maekawa T., Abe H., Fujimoto Y., Tsuge M., Takahashi H., Kumada H., Kamatani N. et al. 2009; A polymorphism in MAPKAPK3 affects response to interferon therapy for chronic hepatitis C. Gastroenterology 136:1796–1805, e6 [View Article][PubMed]
     [Google Scholar]
  38. Urban T. J., Thompson A. J., Bradrick S. S., Fellay J., Schuppan D., Cronin K. D., Hong L., McKenzie A., Patel K. et al. 2010; IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. Hepatology 52:1888–1896 [View Article][PubMed]
     [Google Scholar]
  39. Welzel T. M., Morgan T. R., Bonkovsky H. L., Naishadham D., Pfeiffer R. M., Wright E. C., Hutchinson A. A., Crenshaw A. T., Bashirova A. et al. 2009; Variants in interferon-alpha pathway genes and response to pegylated interferon-alpha2a plus ribavirin for treatment of chronic hepatitis C virus infection in the hepatitis C antiviral long-term treatment against cirrhosis trial. Hepatology 49:1847–1858 [View Article][PubMed]
     [Google Scholar]
  40. Yamaguchi-Kabata Y., Nakazono K., Takahashi A., Saito S., Hosono N., Kubo M., Nakamura Y., Kamatani N. 2008; Japanese population structure, based on SNP genotypes from 7003 individuals compared to other ethnic groups: effects on population-based association studies. Am J Hum Genet 83:445–456 [View Article][PubMed]
     [Google Scholar]
  41. Zhu H., Butera M., Nelson D. R., Liu C. 2005; Novel type I interferon IL-28A suppresses hepatitis C viral RNA replication. Virol J 2:80 [View Article][PubMed]
     [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.029124-0
Loading
IL-28B predicts response to chronic hepatitis C therapy – fine-mapping and replication study in Asian populations
J. Gen. Virol. 92, 1071 (2011); https://doi.org/10.1099/vir.0.029124-0
/content/journal/jgv/10.1099/vir.0.029124-0
/content/journal/jgv/10.1099/vir.0.029124-0
Loading

Data & Media loading...

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error